Alimera Sciences Inc. - notizie pubblicate 237 - letture 2.934
ALIMERA SCIENCES INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer alimera sciences inc. published th ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
Retinal disease is our focus nasdaq: alim september 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include &qu ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
Retinal disease is our focus nasdaq: alim august 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include " ...
ALIMERA SCIENCES INC.
Quarterly Report (SEC Filing - 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) x quarterly report pursuant to section 13 or 15(d) of the securities ...
ALIMERA SCIENCES INC.
Alimera Sciences Announces Second Quarter 2021 Financial Results (Form 8-K)
Alimera sciences announces second quarter 2021 financial results · consolidated net revenue of $21.7million up 117% vs. second quarter of 2020 · consolidated net product reve ...
ALIMERA SCIENCES INC.
OMNIBUS INCENTIVE PLAN (Form 8-K)
2019 omnibus incentive plan as amended pursuant to stockholder approval on june 15, 2021 article i purpose alimera sciences, inc. (the 'company') has establishe ...
ALIMERA SCIENCES INC.
OMNIBUS INCENTIVE PLAN (Form 8-K)
2019 omnibus incentive plan as amended pursuant to stockholder approval on june 15, 2021 article i purpose alimera sciences, inc. (the 'company') has establishe ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
Retinal disease is our focus nasdaq: alim may 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include "for ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
Retinal disease is our focus nasdaq: alim may 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include "for ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
Retinal disease is our focus nasdaq: alim april 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include "f ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
R retinal disease is our focus nasdaq: alim march 2021 this presentation and the conference call and webcast it accompanies include or will include "forward-looking statements ...
ALIMERA SCIENCES INC.
Alimera Sciences Corporate Presentation
R retinal disease is our focus nasdaq: alim march 2021 forward looking statements this presentation and the conference call and webcast it accompanies include or will include " ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti